Anemia is a common condition in premature infants, particularly those at risk for retinopathy of prematurity (ROP).

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

In utero, the fetus receives insulin-like growth factor (IGF-1) via the placenta, which ceases at the time of birth. The infant is predisposed to phase 1 ROP due to an inherent lack of normally ...

Regeneron (REGN) announces FDA review of sBLA for Eylea HD to treat macular edema and expand dosing. Read more here.

The complete response letter did not identify any issues with the safety or efficacy of Eylea HD, Regeneron officials said.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter ...

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

such as retinopathy of prematurity (ROP), to their later years, including diabetic macular edema (DME), diabetic retinopathy (DR), macular edema following retinal vein occlusion (RVO) and wet age ...

Discover surprising truths about blindness, from the spectrum of visual impairment to revolutionary treatments and adaptive ...

A study conducted by Prof Dupe Ademola-Poopola, Dr Kareem Musa et al, titled, “Case Series of Retinopathy of Prematurity Blindness in Nigeria: A Wakeup Call to Policy Makers, Hospitals ...